Symbiosis has provided GMP manufacturing across a wide range of small-molecule applications.
Many small-molecule pharmaceuticals cannot be terminally sterilized using heat or irradiation, requiring aseptic manufacturing processes. Highly-potent molecules may also call for specialist handling requirements within a containment environment.
Throughout our history, we have provided GMP aseptic manufacturing services for small molecule projects, and our dedicated containment suites are equipped to handle highly-potent drugs across the entire filling process.
Gain rapid access to our manufacturing suites to accelerate your small molecule projects and ensure your timelines aren’t missed.
Generally defined as having a molecular mass of fewer than 900 Daltons, the majority of pharmaceuticals are classified as small molecule drugs. These are frequently administered orally for absorption through the stomach or intestine, but can also be administered topically, through inhalation, or via parenteral injection.
Small molecule drugs are often tolerant to terminal sterilization, and may not require an aseptic manufacturing approach if administered parenterally. However, many small molecules cannot tolerate terminal sterilization by heat or irradiation, requiring aseptic manufacturing.
We have extensive experience in taking precious, complex drug products from manufacture to QP release.
Clinical and small scale commercial manufacturing of advanced therapeutics such as viral vectors for cell and gene therapies, oncolytic viruses and critical raw materials such as plasmids.
Extensive experience in delivering hundreds of projects allowing us to support your clinical trials.
Symbiosis can support with challenging manufacturing and handling requirements that need specialist knowledge and experience.
Overcome your development and manufacturing challenges with a partner that has the experience and capabilities to handle your highly potent ADC